New York, Jan 16, 2026, 14:14 ET — Regular session
AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant gain in overall survival, the company said. AbbVie and partner Genmab said they plan to consult regulators on the next steps.
The readout arrives at a sensitive moment for AbbVie stock. Investors are closely tracking how the company plans to sustain growth as its legacy products come under strain, leaving more responsibility on its pipeline to drive results.
AbbVie’s leadership is mapping out plans beyond its immunology core. This week, it highlighted a push into obesity treatments centered on GUBamy — a weight-loss drug licensed from Denmark’s Gubra — positioning it as an alternative to GLP-1 injectables like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. “We’re focusing on tolerability and durability of weight loss,” Chief Medical Officer Roopal Thakkar told the J.P. Morgan Healthcare Conference. Chief Commercial Officer Jeffrey Stewart added that AbbVie’s aesthetics division offers a unique entry point to weight-loss patients. Reuters
In Friday’s lymphoma update, AbbVie highlighted the disconnect between the clinical outcomes that advance drugs and those that actually drive market momentum. Progression-free survival helps sway regulators and payers, yet overall survival remains the clearest benchmark — without it, the next discussion can quickly get complicated.
AbbVie slipped more sharply than the broader healthcare sector, where the Health Care Select Sector SPDR Fund fell roughly 0.4% during the session.
The downside is clear. Missing overall survival in a trial can throw a wrench in label expansion efforts and dampen physician interest—particularly in blood cancers where treatment options evolve rapidly and standards of care constantly shift.
Friday’s session is shortened by the upcoming long weekend. U.S. stock markets shut down Monday, Jan. 19, in observance of Martin Luther King Jr. Day. Trading picks back up Tuesday.
AbbVie is set to release its full-year and fourth-quarter earnings on Feb. 4, ahead of the open. The focus will be on the company’s near-term guidance and its ability to sustain new growth investments without rattling investors, who have little patience for setbacks these days.
Related articles: NYSE:ABBV
